Tonix Pharmaceuticals (NASDAQ: TNXP) , a fully-integrated biopharmaceutical company with commercial products and a robust development pipeline, will ...

Mpox and Smallpox Threats: Vaccine Development and Biosecurity Policy ...

We recently published a list of 10 Stocks Fall Behind Amid Market Optimism. In this article, we are going to take a look at ...

Tonix Pharmaceuticals Holding Corp.’s TNXP share price has dipped by 10.75%, which has investors questioning if this is right ...

Tonix Pharmaceuticals (TNXP) announced a collaborative research agreement under which Tonix and Makana will study Tonix’s anti-CD40L monoclonal ...

(MENAFN- Investor Brand Network) Tonix Pharmaceuticals (NASDAQ: TNXP) announced a research collaboration with Makana Therapeutics to evaluate TNX-1500, its anti-CD40L monoclonal antibody candidate, in ...

Tonix Pharmaceuticals (TNXP) presented data in a poster presentation at the AAPM 2025 Annual Meeting, held April 3-6, 2025, in Austin, Texas.

Stock analysts at Zacks Small Cap issued their Q1 2025 EPS estimates for shares of Tonix Pharmaceuticals in a report released on Thursday, April 3rd. Zacks Small Cap analyst D. Bautz anticipates that ...

According to Benzinga Pro, Tonix Pharmaceuticals's peer group average for short interest as a percentage of float is 11.36%, which means the company has more short interest than most of its peers. Did ...